Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Suvecaltamide - Merck & Co

Drug Profile

Suvecaltamide - Merck & Co

Alternative Names: CX 8998; JZP-385; MK-8998

Latest Information Update: 24 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Cavion; Merck & Co
  • Class Acetamides; Antipsychotics; Ethers; Fluorocarbons; Pyridines; Sleep disorder therapies; Small molecules
  • Mechanism of Action T-type calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Epilepsy; Essential tremor
  • Discontinued Insomnia; Neuropathic pain; Schizophrenia

Most Recent Events

  • 20 Jun 2024 Efficacy and adverse events data from a phase IIb trial in Essential tremor released by Jazz Pharmaceuticals
  • 18 Jun 2024 Discontinued - Phase-II for Schizophrenia in Ukraine, Russia, Croatia, Serbia (PO) before June 2024 (Jazz Pharmaceuticals pipeline, June 2024)
  • 02 May 2024 Jazz Pharmaceuticals completes enrolment in its phase II trial in Essential tremor (In adults, In the elderly) in USA, Poland, Germany, Spain (PO) (EudraCT-2020-002463-61) (NCT05122650)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top